H3-DYNAMICS
15.12.2022 14:34:41 CET | Business Wire | Press release
H3 Dynamics and HyLight have joined forces to bring new long range, sustainable and quiet unmanned airships to a range of commercial applications. Traditionally, airships use combustion engines for their propulsion power. With new hydrogen propulsion system developments at H3 Dynamics, HyLight’s new breed of airships will now offer long-range zero emission flight and open a whole new category in air mobility. The two companies share a common goal, to decarbonize the aerial industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221215005555/en/
HyLight’s compact airship is powered by H3 Dynamics hydrogen air-mobility power systems
HyLight and H3 Dynamics started working together several months ago in France, and HyLight have now achieved a first successful hydrogen-electric flight test campaign in Milan, Italy. HyLight is an up and coming french start-up and one of the very few companies in the world that was able to demonstrate hydrogen as a viable power supply for small unmanned airships in real conditions. This was made possible with H3 Dynamics’ aerospace-grade hydrogen fuel cells - the smallest and lightest in the world - have pioneered hydrogen flight research from as early 2006.
HyLight’s unmanned airships move slowly but don’t need to consume any power to stay aloft. They can operate for days at a time with heavier payloads compared to conventional drones, to conduct long range inspection of critical energy assets like power-lines & pipelines or scan industrial infrastructure over long distances. Airships could also hover around specific areas to provide critical connectivity for large scale industrial sites - or provide vital communications after a natural disaster.
Based in Toulouse, H3 Dynamics is set on decarbonizing air mobility with clean hydrogen-electric propulsion, starting with enabling smaller unmanned systems - whether fixed wing, multi-rotor or VTOL platforms. Its ultra-light power technology is bringing new long electric flight durations to the global unmanned aviation market, which is set to reach $38 Billion by 2027.
Earlier this year H3 Dynamics flew the world’s first distributed hydrogen-electric nacelles on a small unmanned platform, proving the potential for larger size systems in bigger aircraft. H3 Dynamics has since become part of the “Toulouse Pioneers” group linked to the Aerospace History Museum “L’Envol des Pionniers”. The company plans to scale its solutions to larger unmanned and manned aviation platforms over the coming years.
HyLight will leverage H3 Dynamics’ international presence covering Europe, North and South America as well as Asia and Australia to bring “made in France” hydrogen-electric airships to the global market.
About HyLight: https://www.hylight.aero
HyLight wants to decarbonize the aerial data industry by providing long-range aerial data collection and analysis services using its unmanned airship systems for the inspection of power lines, pipelines, and railways. Its airship come with hydrogen electric propulsion making them sustainable, silent, efficient, and long-range to cover large areas or distances. The company was started in France and has recently demonstrated the first flight of its hydrogen-electric platform. HyLight was selected to participate in the 1st Batch of the acceleration program of Berkeley SkyDeck Europe, Milano ; the company is also a member of the Hub Drone Systematic and U-LTA and has been financially supported by La Région Grand Est in France.
About H3 Dynamics www.h3dynamics.com
H3 Dynamics is based in Toulouse, Austin and Singapore - and is on a mission to decarbonize aviation with a unique technology solution around distributed hydrogen-electric propulsion, as well as ground refueling solutions. The company’s initial commercial focus is on the scale up of autonomous digital services that link to networks of charging stations for off-the-shelf battery-drones, making way for BVLOS hydrogen UAS capability. H3 Dynamics is a member of the Alliance for Zero Emission Aviation under the European Commission, Sustainable Aero Lab, the Lufthansa Cleantech Hub, the Paris Advanced Air Mobility Alliance, and Aerospace Valley in Toulouse.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005555/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom